• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

IJERPH, Vol. 20, Pages 6145: Anticoagulant Treatment in Patients with AF and Very High Thromboembolic Risk in the Era before and after the Introduction of NOAC: Observation at a Polish Reference Centre
This study outlines reasons to initiate OAC treatment in very high-risk patients in clinical practice.
Source: International Journal of Environmental Research and Public Health - June 16, 2023 Category: Environmental Health Authors: Bernadetta Bielecka Iwona Gorczyca-G łowacka Agnieszka Ciba-Stemplewska Beata Wo żakowska-Kapłon Tags: Article Source Type: research

IJERPH, Vol. 19, Pages 11939: Do Patients with Atrial Fibrillation and a History of Ischemic Stroke Overuse Reduced Doses of NOACs? & mdash;Results of the Polish Atrial Fibrillation (POL-AF) Registry
Conclusions: A significant proportion of AF patients received reduced doses of NOAC after ischemic stroke in a sizeable number of cases, without indication for dose reduction.
Source: International Journal of Environmental Research and Public Health - September 21, 2022 Category: Environmental Health Authors: Anna Szyszkowska Łukasz Kuźma Beata Wo żakowska-Kapłon Iwona Gorczyca-G łowacka Olga Jelonek Beata Uzi ębło-Życzkowska Pawe ł Krzesiński Maciej W ójcik Robert B łaszczyk Monika Gawa łko Agnieszka Kap łon-Cieślicka Tomasz Tokarek Renata Rajt Tags: Article Source Type: research

Optimal anticoagulation in elderly patients with atrial fibrillation: Which drug at which dose?
Kardiol Pol. 2022 Feb 15. doi: 10.33963/KP.a2022.0046. Online ahead of print.ABSTRACTAging is an important risk factor of adverse events in elderly patients with atrial fibrillation (AF) and complicates the management of anticoagulation. Underuse of oral anticoagulants (OACs) is common in elderly patients because of comorbidities, altered physiological function of multiple organs, fragile features, risk of falls, and the lack of randomized controlled trials (RCTs) specifically for elderly patients. Nevertheless, current data still support OACs use for reducing ischemic stroke with positive net clinical benefits. Sub-analys...
Source: Polish Heart Journal - February 15, 2022 Category: Cardiology Authors: Jo-Nan Liao Yi-Hsin Chan Ling Kuo Chuan-Tsai Tsai Su-Shen Lim Tze-Fan Chao Source Type: research

Antiphosholipid syndrome and the risk of myocardial infarction: current evidence and uncertainties.
Abstract Antiphospholipid syndrome (APS) encompasses a wide spectrum of disease manifestations that may prevail in the form of venous or arterial thrombosis or lead to pregnancy complications in the presence of persisting antiphospholipid (aPL) antibodies. Unlike in the case of congenital thrombophilias where venous thromboses are more likely to occur as compared to arterial events, aPL antibodies may cause thrombosis in both types of vascular system, often including the coronary or cerebral arteries leading to myocardial infarction (MI) or stroke. In this review we summarize the complex pathomechanisms leading to...
Source: Polish Heart Journal - December 5, 2019 Category: Cardiology Authors: Lóczi L, Kappelmayer J, Tarr T, Bagoly Z Tags: Kardiol Pol Source Type: research

What Causes Facial Nerve Palsy?
Discussion Facial nerve palsy has been known for centuries, but in 1821 unilateral facial nerve paralysis was described by Sir Charles Bell. Bell’s palsy (BP) is a unilateral, acute facial paralysis that is clinically diagnosed after other etiologies have been excluded by appropriate history, physical examination and/or laboratory testing or imaging. Symptoms include abnormal movement of facial nerve. It can be associated with changes in facial sensation, hearing, taste or excessive tearing. The right and left sides are equally affected but bilateral BP is rare (0.3%). Paralysis can be complete or incomplete at prese...
Source: PediatricEducation.org - June 3, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Non-vitamin K antagonist oral anticoagulants (NOACs) in the treatment of coronary and peripheral atherosclerosis. Expert Consensus.
Abstract Oral anticoagulants (OAC) are widely used for prevention of systemic thromboembolism, including the reduction of the risk of stroke in patients with atrial fibrillation (AF) and prosthetic heart valves. There is also an increasing population of patients who require not only OACs, but also double antiplatelet therapy (DAPT). A typical example is a patient with AF and stable coronary artery disease or acute coronary syndrome (ACS), treated by percutaneous coronary intervention (PCI). In recent years, with the introduction of NOACs, triple or dual therapy has become safer. Regardless of these indications for...
Source: Polish Heart Journal - February 25, 2019 Category: Cardiology Authors: Witkowski A, Barylski M, Filipiak KJ, Gierlotka M, Legutko J, Lesiak M, Stępińska J, Wojakowski W Tags: Kardiol Pol Source Type: research

Differences in knowledge among patients with atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants and vitamin K antagonists.
CONCLUSIONS: The knowledge of arrhythmia and anticoagulation is better regarding the safety issues among subjects on NOACs compared with those on VKAs. Irrespective of the type of oral anticoagulation therapy, education of AF patients should be improved. PMID: 29528483 [PubMed - indexed for MEDLINE]
Source: Kardiologia Polska - November 8, 2018 Category: Cardiology Authors: Konieczyńska M, Sobieraj E, Bryk AH, Dębski M, Polak M, Podolec P, Małecka B, Pająk A, Desteghe L, Heidbuchel H, Undas A Tags: Kardiol Pol Source Type: research

Differences in knowledge among patients with atrial fibrillation receiving NOACs and vitamin K antagonists.
CONCLUSIONS: The knowledge of arrhythmia and anticoagulation is better regarding the safety issues among subjects on NOACs compared with VKA. Irrespective of the type of OAC therapy, education of AF patients should be improved. PMID: 29528483 [PubMed - as supplied by publisher]
Source: Polish Heart Journal - March 12, 2018 Category: Cardiology Authors: Konieczyńska M, Sobieraj E, Bryk AH, Dębski M, Polak M, Podolec P, Małecka B, Pająk A, Desteghe L, Heidbuchel H, Undas A Tags: Kardiol Pol Source Type: research

Pharmacological stroke prevention in the elderly with atrial fibrillation in Poland – Results of PolSenior study
Conclusions The study was unique to determine the frequency of pharmacological stroke prevention among elderly people with AF in Poland. It occurred that oral anticoagulant drugs were applied too rarely in this group of patients. Educational programs should be developed among general practitioners concerning current recommendations for patients with AF.
Source: Polish Journal of Neurology and Neurosurgery - July 12, 2017 Category: Neurosurgery Source Type: research

Polish and European management strategies in patients with atrial fibrillation. Data from the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot).
CONCLUSIONS    A rhythm control-oriented strategy in patients with AF with the use of ablation in cardiology wards is more frequent in Poland than in other EU countries. Similar to other EU countries, compliance with the ESC guidelines regarding anticoagulation in AF patients is suboptimal in Poland. Undertreatment was observed in a significant proportion of patients at high risk of stroke, while a large group of low-risk patients are overtreated. Differences between the types of recruiting centers in Poland and other EU countries might have influenced the results. PMID: 27000745 [PubMed - as supplied by publisher]
Source: Polskie Archiwum Medycyny Wewnetrznej - March 25, 2016 Category: Internal Medicine Tags: Pol Arch Med Wewn Source Type: research

Stroke prevention in AF patients in Poland and other European countries: insights from the GARFIELD-AF registry.
CONCLUSIONS: The GARFIELD-AF Registry data shows how distant every day clinical practice is from the guidelines. It shows that still in Poland, as well as in the rest of Europe, too many patients with low stroke risk are treated with anticoagulants, while too frequently patients at the high stroke risk are left with no stroke prevention. Although the tendency to use non-vitamin K oral anticoagulants grows comparably in Poland and in the rest of Europe, the proportion of patients with intermediate and high stroke risk does not grow and more patients at low stroke risk are treated with anticoagulants. PMID: 26365937 [Pu...
Source: Polish Heart Journal - September 14, 2015 Category: Cardiology Authors: Stępińska J, Kremis E, Konopka A, Wożakowska-Kapłon B, Ruszkowski P, Kukla P, Kayani G Tags: Kardiol Pol Source Type: research